What It Is
Retatrutide, also known by its development code LY3437943, is an investigational peptide-class "triple agonist" designed to activate three separate metabolic hormone receptors at once: GIP, GLP-1, and glucagon.[1] Eli Lilly is developing it for obesity, type 2 diabetes, and related metabolic conditions, but it is not an FDA-approved drug and has no approved prescription product on the market.
Retatrutide is often discussed alongside tirzepatide, a dual GIP/GLP-1 agonist, and semaglutide, a GLP-1-only agonist. Unlike those two, retatrutide remains in Phase 3 clinical trials rather than approved labeling, and its results should be read as investigational until regulators complete their review.[2]
How It Works
Retatrutide combines activity at the glucose-dependent insulinotropic polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R), and the glucagon receptor (GCGR) in a single molecule.[1] GLP-1 receptor activity is associated with glucose-dependent insulin release, slowed gastric emptying, and reduced appetite; GIP receptor activity contributes to post-meal insulin response; and glucagon receptor activity — the feature that distinguishes retatrutide from GLP-1-only or dual GIP/GLP-1 drugs — is thought to influence energy expenditure and fat metabolism.[3]
This three-pathway design is biologically plausible and consistent with incretin physiology, but mechanism alone does not establish a clinical outcome; that requires trial data.
What the Research Shows
Retatrutide has produced some of the largest weight-loss figures reported in peptide-based metabolic trials to date. In a Phase 2 obesity trial, participants on the highest doses lost an average of roughly 22–24% of body weight at 48 weeks.[4] Eli Lilly's 2026 Phase 3 TRIUMPH-1 topline results reported an average reduction of about 28% of body weight at 80 weeks in the highest-dose group — larger than typical figures for currently approved GLP-1 or GLP-1/GIP therapies, though cross-trial comparisons should be read cautiously given differing designs and populations.[5]
In type 2 diabetes trials, retatrutide produced dose-dependent HbA1c reductions of roughly 1.7 to 2 percentage points, and an early MASLD substudy reported large reductions in liver fat.[6] These are meaningful research signals rather than approved-label outcomes, and long-term cardiovascular and safety endpoints are still being evaluated.
Safety & Side Effects
Reported side effects are predominantly gastrointestinal — nausea, diarrhea, vomiting, and constipation — with frequency rising alongside higher doses and faster dose escalation. In one Phase 3 diabetes trial, nausea occurred in roughly 16 to 27% of retatrutide-treated participants across dose groups, compared with under 4% on placebo, and adverse-event discontinuation reached about 5% in higher-dose groups.[7]
Because retatrutide is not FDA-approved, there is no approved label defining contraindications, drug interactions, or special-population guidance. Pancreatitis history, gallbladder disease, pregnancy, and breastfeeding are reasonable safety questions by analogy with related incretin drugs, but retatrutide-specific human data remain limited.[8]
Regulatory Status
Retatrutide is investigational only. The FDA has stated it is not a component of any FDA-approved drug and has not been found safe and effective for any condition.[9] It remains in Phase 3 trials for obesity and type 2 diabetes, with regulatory review and any potential approval still pending.
The FDA has also stated explicitly that retatrutide cannot legally be used in compounding, and warns that unapproved GLP-1-class products sold online should not be treated as equivalent to reviewed pharmaceuticals.[9] Any retatrutide sold today as a "research peptide" exists entirely outside FDA oversight for manufacturing quality, purity, or dosing accuracy.
Retatrutide vs. Approved Incretin Therapies
Semaglutide (GLP-1 only) and tirzepatide (dual GIP/GLP-1) both have FDA-approved products; retatrutide's added glucagon receptor activity is what separates it mechanistically, and its trial-reported weight loss has so far exceeded both in cross-trial comparisons.[5] A registered head-to-head Phase 3 trial against tirzepatide is underway and should eventually provide more direct evidence. Until then, retatrutide's larger effect sizes should be weighed against its earlier stage of review and a smaller safety database than either approved drug.